News & Updates
Showing Multidisciplinary articles
Showing
Infliximab does not contribute to long-term weight gain in IBD patients
Treatment with infliximab does not lead to a general long-term weight gain in patients with inflammatory bowel disease (IBD), claims a study.
Infliximab does not contribute to long-term weight gain in IBD patients
20 May 2022
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
20 May 2022
Focus points of healthy ageing to 100 years and beyond
Increasingly low birth rates and longevity are predicted to result in 2 billion people aged above 60 on the planet by middle of this century.
Focus points of healthy ageing to 100 years and beyond
20 May 2022
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
Patients who have had a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are likely to experience a recurrent ischaemic stroke episode and bleeding, according to data from the RENO-EXTEND Study.
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
20 May 2022
Sustained benefits with ocrelizumab in relapsing-remitting MS
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
